We used cell models for hepatocellular carcinoma (HepG2), tamoxifen-resistant estrogen receptor-positive breast cancer (MCF7/TR), triple-negative breast cancer (MDA-MB231) and tested the effects of tazemetostat (TAZ) on GPX4 and SLC7A11 gene expression evidencing a significant increase of both genes in all tumor cell models (Fig. 6A–C). This evidence concerns the gene SLC7A11 and triple-negative breast carcinoma.